2023-05-03 16:13:15 ET
-
ImmunoGen ( NASDAQ: IMGN ) said Wednesday it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering.
-
ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of common stock.
-
All of the shares of common stock to be sold in the offering are to be offered by ImmunoGen.
-
Net proceeds from the offering will be used to fund operations, including, but not limited to, global commercialization activities, supply of ELAHERE drug product, among other things.
-
Jefferies, Goldman Sachs, and Guggenheim Securities are acting as joint book-running managers for the proposed offering.
For further details see:
ImmunoGen proposes $200M stock offering